Evidence map›Paper›PMID 36331674›Full record

ArticleInvestigational new drugs2023

Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study.

Toshio Shimizu, Kazuhiko Nakagawa, Hidetoshi Hayashi, Tsutomu Iwasa, Hisato Kawakami, Satomi Watanabe, Noboru Yamamoto, Kan Yonemori, Takafumi Koyama, Jun Sato and 5 more

Open access · hybridFull text readMulticenter StudyClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Toshio ShimizuDepartment of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, Japan. sentants@wakayama-med.ac.jp.
Kazuhiko NakagawaDepartment of Medical Oncology, Kindai University Faculty of Medicine, 377-2, Osakasayama-city, Osaka, Japan.
Hidetoshi HayashiDepartment of Medical Oncology, Kindai University Faculty of Medicine, 377-2, Osakasayama-city, Osaka, Japan.
Tsutomu IwasaDepartment of Medical Oncology, Kindai University Faculty of Medicine, 377-2, Osakasayama-city, Osaka, Japan.
Hisato KawakamiDepartment of Medical Oncology, Kindai University Faculty of Medicine, 377-2, Osakasayama-city, Osaka, Japan.
Satomi WatanabeDepartment of Medical Oncology, Kindai University Faculty of Medicine, 377-2, Osakasayama-city, Osaka, Japan.
Noboru YamamotoDepartment of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, Japan.
Kan YonemoriDepartment of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, Japan.
Takafumi KoyamaDepartment of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, Japan.
Jun SatoDepartment of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, Japan.
Kenji TamuraDepartment of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo, Japan.
Keiichi KikuchiSymBio Pharmaceuticals Limited, 3-2-2 Toranomon, Minato-ku, Tokyo, Japan.
Kenichiro AkaikeSymBio Pharmaceuticals Limited, 3-2-2 Toranomon, Minato-ku, Tokyo, Japan.
Shiho TakedaSymBio Pharmaceuticals Limited, 3-2-2 Toranomon, Minato-ku, Tokyo, Japan.
Masayuki TakedaDepartment of Medical Oncology, Kindai University Faculty of Medicine, 377-2, Osakasayama-city, Osaka, Japan.
Kindai University · JPShimane University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To determine the maximum tolerated dose (MTD) and recommended dose (RD) of orally-administered bendamustine in Japanese patients with advanced solid tumors. The optimal dosing schedule, safety, pharmacokinetics, and preliminary antitumor effects were also evaluated. A multicenter, open-label trial with a standard 3 + 3 design and dose escalation by dose-limiting toxicity (DLT) was conducted. The treatment schedules were once daily for 7, 14, and 21 days every 3 weeks as one cycle. The total dose per cycle was increased from 175 to 840 mg/m

Indexed as

NeoplasmsBendamustine HydrochlorideHumansMaximum Tolerated DoseBendamustine HydrochlorideBendamustineOral formulationPharmacokineticsPhase I studySolid tumor

Identifiers

PMID36331674
PMCPMC10030450
OpenAlexW4308182479

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read88
identifiers read2
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.